End-of-day quote
Dhaka S.E.
06:00:00 2024-04-24 pm EDT
|
5-day change
|
1st Jan Change
|
207.7
BDT
|
-2.07%
|
|
-2.99%
|
-1.24%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
208,535
|
145,631
|
191,030
|
192,094
|
185,977
|
184,116
|
-
|
-
|
Enterprise Value (EV)
1 |
208,535
|
113,067
|
147,770
|
140,679
|
137,870
|
184,116
|
184,116
|
184,116
|
P/E ratio
|
-
|
10.4
x
|
12
x
|
10.6
x
|
9.8
x
|
8.69
x
|
7.46
x
|
6.64
x
|
Yield
|
1.7%
|
2.86%
|
2.78%
|
4.61%
|
5%
|
4.94%
|
5.42%
|
6.02%
|
Capitalization / Revenue
|
4.74
x
|
3.17
x
|
3.77
x
|
3.34
x
|
2.96
x
|
2.56
x
|
2.27
x
|
2.03
x
|
EV / Revenue
|
4.74
x
|
3.17
x
|
3.77
x
|
3.34
x
|
2.96
x
|
2.56
x
|
2.27
x
|
2.03
x
|
EV / EBITDA
|
12.9
x
|
8.72
x
|
10.6
x
|
9.5
x
|
9.01
x
|
8.1
x
|
7.1
x
|
6.32
x
|
EV / FCF
|
20.2
x
|
16.7
x
|
26.4
x
|
19.8
x
|
32.5
x
|
13.1
x
|
11.1
x
|
11.5
x
|
FCF Yield
|
4.96%
|
5.99%
|
3.78%
|
5.06%
|
3.08%
|
7.61%
|
9%
|
8.69%
|
Price to Book
|
2.87
x
|
1.79
x
|
2.1
x
|
1.86
x
|
1.61
x
|
1.45
x
|
1.3
x
|
1.17
x
|
Nbr of stocks (in thousands)
|
886,451
|
886,451
|
886,451
|
886,451
|
886,451
|
886,451
|
-
|
-
|
Reference price
2 |
235.2
|
164.3
|
215.5
|
216.7
|
209.8
|
207.7
|
207.7
|
207.7
|
Announcement Date
|
11/27/19
|
12/1/20
|
11/25/21
|
12/4/22
|
11/22/23
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
44,034
|
45,876
|
50,703
|
57,598
|
62,748
|
71,990
|
81,075
|
90,892
|
EBITDA
1 |
16,170
|
16,701
|
18,009
|
20,218
|
20,651
|
22,740
|
25,935
|
29,122
|
EBIT
1 |
14,143
|
14,731
|
16,126
|
18,383
|
18,341
|
20,298
|
23,710
|
26,662
|
Operating Margin
|
32.12%
|
32.11%
|
31.81%
|
31.92%
|
29.23%
|
28.2%
|
29.24%
|
29.33%
|
Earnings before Tax (EBT)
1 |
-
|
16,998
|
18,756
|
21,025
|
21,099
|
25,436
|
28,834
|
32,467
|
Net income
1 |
-
|
13,354
|
14,743
|
16,417
|
18,858
|
21,495
|
24,667
|
27,725
|
Net margin
|
-
|
29.11%
|
29.08%
|
28.5%
|
30.05%
|
29.86%
|
30.42%
|
30.5%
|
EPS
2 |
-
|
15.82
|
17.99
|
20.51
|
21.41
|
23.90
|
27.83
|
31.28
|
Free Cash Flow
1 |
10,343
|
8,719
|
7,223
|
9,713
|
5,721
|
14,004
|
16,563
|
15,996
|
FCF margin
|
23.49%
|
19%
|
14.25%
|
16.86%
|
9.12%
|
19.45%
|
20.43%
|
17.6%
|
FCF Conversion (EBITDA)
|
63.96%
|
52.21%
|
40.11%
|
48.04%
|
27.71%
|
61.58%
|
63.86%
|
54.93%
|
FCF Conversion (Net income)
|
-
|
65.29%
|
48.99%
|
59.16%
|
30.34%
|
65.15%
|
67.15%
|
57.7%
|
Dividend per Share
2 |
4.000
|
4.700
|
6.000
|
10.00
|
10.50
|
10.25
|
11.25
|
12.50
|
Announcement Date
|
11/27/19
|
12/1/20
|
11/25/21
|
12/4/22
|
11/22/23
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
32,564
|
43,260
|
51,415
|
48,107
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
10,343
|
8,719
|
7,223
|
9,713
|
5,721
|
14,004
|
16,563
|
15,996
|
ROE (net income / shareholders' equity)
|
20.1%
|
18.4%
|
17.5%
|
18.7%
|
17.1%
|
17.3%
|
17.9%
|
18.1%
|
ROA (Net income/ Total Assets)
|
19%
|
17.3%
|
16.6%
|
17.7%
|
16.1%
|
16.4%
|
17%
|
17.2%
|
Assets
1 |
-
|
76,983
|
88,636
|
92,778
|
116,787
|
131,468
|
145,100
|
161,192
|
Book Value Per Share
2 |
81.90
|
91.60
|
103.0
|
117.0
|
130.0
|
144.0
|
160.0
|
178.0
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
9.640
|
26.50
|
29.60
|
33.30
|
Capex
|
2,049
|
2,042
|
3,798
|
6,052
|
-
|
-
|
-
|
-
|
Capex / Sales
|
4.65%
|
4.45%
|
7.49%
|
10.51%
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/27/19
|
12/1/20
|
11/25/21
|
12/4/22
|
11/22/23
|
-
|
-
|
-
|
Last Close Price
207.7
BDT Average target price
321.8
BDT Spread / Average Target +54.91% Consensus |
1st Jan change
|
Capi.
|
---|
| -1.24% | 1.68B | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|